JANA Partners Urges Markel Group to Divest Ventures in Activist Showdown

GLEN ALLEN, VA – April 30, 2026 – Activist investor JANA Partners today fired a direct shot at the core identity of Markel Group Inc. (NYSE: MKL), publicly calling on the company’s board to dismantle its long-standing diversified structure. In a sharply worded letter, the New York-based hedge fund demanded that Markel divest its entire Markel Ventures portfolio of non-insurance businesses and execute a $2 billion share repurchase to combat what JANA termed “persistent undervaluation” and a decade of poor shareholder returns.

The move sets the stage for a potential battle over the future of a company often called a “mini-Berkshire Hathaway” for its dual strategy of combining a world-class specialty insurance operation with a collection of disparate industrial and consumer businesses. JANA's ultimatum challenges the very foundation of “The Markel Way,” the company's celebrated philosophy of long-term, patient capital allocation across a diversified enterprise.

A Case Built on Underperformance

At the heart of JANA’s argument is a blunt assessment of Markel’s performance. The letter, signed by Managing Partner Scott Ostfeld and Managing Director Jimmy Ganas, claims the company’s stock has been a chronic laggard. “The need for change is clear: Markel ranks last in returns vs. its 16 proxy peers over the past decade and last in returns vs. the 5 insurance peers it cited at its 2025 Omaha Brunch over that same timeframe,” the letter states.

JANA argues that the market has decisively rejected Markel’s combined structure, assigning it a discounted valuation multiple. The activist firm contends that any previous excuses for this underperformance—such as a struggling insurance segment or a lack of understanding from Wall Street—are no longer valid. JANA credits Markel’s new leadership with a “dramatic improvement in insurance operations” but argues this success is being overshadowed and held back by the Ventures segment.

This “conglomerate discount” is a classic target for activist investors, who often argue that a company’s individual parts are worth more separately than they are combined. By presenting data showing Markel at the bottom of its peer group on both shareholder returns and price-to-book valuation, JANA is making a clear, numbers-driven case that the current strategy has failed to deliver for its public owners. The letter also took a swipe at the board, noting that management received maximum payouts for its five-year shareholder return metrics despite lagging most peers over the same period.

A Challenge to 'The Markel Way'

JANA's demands represent a fundamental challenge to a corporate identity that has been decades in the making. Markel has long prided itself on its unique, three-engine model of insurance, investments, and Markel Ventures. The rationale has always been that the diverse, non-correlated earnings from the Ventures businesses—which include everything from bakery equipment manufacturers to luxury handbag makers and residential construction companies—provide a stable cash flow stream that smooths out the inherent cyclicality of the insurance market.

Management has consistently preached that Ventures is not a collection of assets to be traded but a portfolio of good businesses given a “forever home” where they can grow with the support of Markel’s permanent capital base. JANA’s letter directly confronts this philosophy.

“The Board cannot allow fealty to its Ventures entrepreneurs (to whom it promised a forever home) to stand in the way of doing what is right for Markel shareholders (to whom it owes its actual fiduciary duties),” the letter asserts. This statement frames the conflict as one of fiduciary responsibility to investors versus a cultural commitment to acquired companies, a distinction designed to pressure the board.

Markel’s leadership has historically been steadfast in defending its integrated model, arguing that it provides unique flexibility for capital allocation and creates a resilient enterprise built for long-term compounding. The activist's public campaign now forces the company to defend that strategy not just in investor presentations, but in a high-stakes public forum.

The Sum-of-the-Parts Argument

Beyond philosophical differences, JANA's plan is rooted in financial engineering. The activist firm believes that Markel’s specialty insurance franchise is an attractive, high-performing asset that is being “held hostage” by the Ventures conglomerate. By spinning off or selling Ventures, JANA argues, Markel would become a pure-play specialty insurer, a category of companies that often command higher valuation multiples from investors who favor focused, easy-to-understand businesses.

JANA also claims the diversification strategy has acted as a “poison pill,” preventing shareholders from realizing the value that could come from strategic interest in Markel’s insurance operations. A simplified corporate structure, the argument goes, could make Markel a more attractive target for acquisition or other strategic partnerships within the insurance industry.

To accelerate this value creation, JANA is also calling for a $2 billion tender offer to repurchase shares. This would serve two purposes: first, it would immediately return a significant amount of capital to shareholders at what JANA considers a discounted price. Second, it would demonstrate the board's conviction that the stock is undervalued, a powerful signal to the market ahead of a potential divestiture of the Ventures arm.

A Familiar Playbook and an Uncertain Road Ahead

For JANA Partners, founded by Barry Rosenstein in 2001, this campaign follows a well-worn activist playbook. The firm has a long and often successful history of pushing companies to make major strategic changes, including divestitures and spin-offs. Its past campaigns at companies like Whole Foods (which was sold to Amazon), ConAgra Brands (which spun off its Lamb Weston business), and Freshpet have shown its ability to force management and boards to reconsider long-held strategies.

The ball is now in Markel’s court. The company’s board must decide how to respond to a public attack from a credible and determined activist. An initial response will likely involve a statement acknowledging receipt of the letter and affirming the board’s commitment to shareholder value. Behind the scenes, however, a frantic process of evaluating JANA’s claims, engaging with major institutional shareholders, and preparing a defense of its strategy is almost certainly underway.

Markel's path forward is fraught with complexity. It can choose to fight, defending “The Markel Way” and potentially facing a costly and distracting proxy battle for board seats. Alternatively, it could seek a compromise, perhaps by agreeing to a larger share buyback or a strategic review of the Ventures portfolio without committing to a full divestiture. The ultimate outcome will likely be determined by the powerful, and often quiet, institutional investors who hold the majority of Markel’s shares. The financial world now waits to see if 'The Markel Way' can withstand the pressure of a determined and experienced activist investor.